Detalhe da pesquisa
1.
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.
Front Immunol
; 13: 1015585, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263022